Previous Article | Next Article ![]()
Journal of Virology, December 1999, p. 10129-10136, Vol. 73, No. 12
Department of Antiviral Therapy,
Schering-Plough Research Institute, Kenilworth, New
Jersey,1 and Department of Biology,
Indiana University, Bloomington, Indiana2
Received 21 April 1999/Accepted 27 August 1999
Recombinant bovine viral diarrhea virus (BVDV) nonstructural
protein 5B (NS5B) produced in insect cells has been shown to possess an
RNA-dependent RNA polymerase (RdRp) activity. Our initial attempt to
produce the full-length BVDV NS5B with a C-terminal hexahistidine tag
in Escherichia coli failed due to the expression of
insoluble products. Prompted by a recent report that removal of the
C-terminal hydrophobic domain significantly improved the solubility of
hepatitis C virus (HCV) NS5B, we constructed a similar deletion of 24 amino acids at the C terminus of BVDV NS5B. The resulting fusion
protein, NS5B
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Mutational Analysis of Bovine Viral Diarrhea Virus
RNA-Dependent RNA Polymerase
CT24-His, was purified to homogeneity and demonstrated
to direct RNA replication via both primer-dependent (elongative) and
primer-independent (de novo) mechanisms. Furthermore, BVDV RdRp was
found to utilize a circular single-stranded DNA as a template for RNA
synthesis, suggesting that synthesis does not require ends in the
template. In addition to the previously described polymerase motifs A,
B, C, and D, alignments with other flavivirus sequences revealed two
additional motifs, one N-terminal to motif A and one C-terminal to
motif D. Extensive alanine substitutions showed that while most
mutations had similar effects on both elongative and de novo RNA
syntheses, some had selective effects. Finally, deletions of up to 90 amino acids from the N terminus did not significantly affect RdRp
activities, whereas deletions of more than 24 amino acids at the C
terminus resulted in either insoluble products or soluble proteins
(
CT179 and
CT218) that lacked RdRp activities.
*
Corresponding author. Mailing address: Department of
Antiviral Therapy, K-15-4650, Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033-0539. Phone: (908) 740-3451. Fax: (908) 740-3918. E-mail: johnson.lau{at}spcorp.com.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|